Cardiovascular and metabolic effects of Berberine

Affuso, Flora; Mercurio, Valentina; Fazio, Valeria; Fazio, Serafino

doi:10.4330/wjc.v2.i4.71

Cited by 81 publications

(48 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have demonstrated that BBR has remarkable effects as an anti-hyperglycemic, anti-hyperlipidemic and it reduces weight gain in T2D patients (Yin et al 2008;Zhang et al 2010;Zhao et al 2008). In addition, the beneficial effects of BBR on cardiovascular, liver and renal disease have been demonstrated in both pre-clinical and clinical research (Cheng et al 2013;Derosa et al 2013;Affuso et al 2010;Marin-Neto et al 1988;Zhao et al 2008;Lan et al 2010). These observations make BBR a potentially promising drug for the management of T2D.…”

Section: Page 3 Of 39mentioning

confidence: 95%

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Chang

Chen

Hatch

2015

Biochem. Cell Biol.

129

View full text Add to dashboard Cite

The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging. However, most anti-diabetic drugs cannot be used in patients with hepatic dysfunction, renal disease, and heart disease, which makes pharmacological therapy of type 2 diabetes complicated. Despite continued introduction of novel agents, the search for an ideal drug that is useful as both a hypoglycemic agent and to reduce diabetes-related complications remains elusive. Berberine is an isoquinoline alkaloid extract that has shown promise as a hypoglycemic agent in the management of diabetes in animal and human studies. Mechanistic studies have revealed beneficial effects of berberine on diabetes-related complications. Although there have been few clinical reports of the anti-diabetic effects of berberine, little documentation of adverse effects in humans positions it as a potential candidate drug to treat type 2 diabetes. In the present review, the anti-diabetic mechanism of berberine, its effect on diabetes-related complications, and its recent use in human clinical studies is highlighted. In addition, we summarize the different treatments for type 2 diabetes in adults and children.

show abstract

Section: Page 3 Of 39mentioning

confidence: 95%

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Chang

Chen

Hatch

2015

Biochem. Cell Biol.

129

View full text Add to dashboard Cite

show abstract

“…Berberine is an alkaloid of the protoberberine type, and is present in an array of plants such as Coptis chinensis [106, 107]. It is reported that this plant has been used for medicinal purposes for more than 2500 years in Ayurvedic and Chinese medicine [108]. Traditionally, berberine is used as an antimicrobial and antiprotozoal agent, which has been employed in Chinese medicine for many decades [107].…”

Section: Metformin Versus Other Agentsmentioning

confidence: 99%

“…Although, the exact mechanisms of berberine effects remain poorly understood, AMPK [110], PPAR γ [111], PKC [112], glucagon-like peptide 2 [113], antioxidant and anti-inflammatory activities [114], increased insulin receptor expression [115], and 11β-hydroxysteroid dehydrogenase [108] are likely involved in the underlying beneficial effects of berberine. Additionally, it is hypothesized that modulating gut microbiota may be another anti-diabetic mechanism for berberine actions [116].…”

Section: Metformin Versus Other Agentsmentioning

confidence: 99%

Metformin and metabolic diseases: a focus on hepatic aspects

Zheng

Woo

et al. 2015

Front. Med.

View full text Add to dashboard Cite

Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses hepatic glucose production (HGP), serving as the main mechanism by which metformin improves hyperglycemia of T2D. Biochemically, metformin suppresses gluconeogenesis and stimulates glycolysis. Metformin also inhibits glycogenolysis, which is a pathway that critically contributes to elevated HGP. While generating beneficial effects on hyperglycemia, metformin also improves insulin resistance and corrects dyslipidemia in patients with T2D. These beneficial effects of metformin implicate a role for metformin in managing non-alcoholic fatty liver disease. As supported by the results from both human and animal studies, metformin improves hepatic steatosis and suppresses liver inflammation. Mechanistically, the beneficial effects of metformin on hepatic aspects are mediated through both adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. In addition, metformin is generally safe and may also benefit patients with other chronic liver diseases.

show abstract

“…Berberine, a natural compound isolated from Chinese medicinal herbs such as Cortexphellodendri and Rhizoma coptidis, possesses significant antiinflammatory effects and has been used clinically to treat chronic inflammation-associated diseases such as diabetes (1,2), hypertension (3,4) and dyslipidemia (5)(6)(7). In vivo animal studies have shown that berberine can attenuate acute lung injury and improve survival in endotoxemic mice which is mediated, at least in part, by the modulation of cytokine production (8).…”

mentioning

confidence: 99%

Berberine Reduces Leukocyte Adhesion to Lps-Stimulated Endothelial Cells and Vcam-1 Expression Both In Vivo and In Vitro

et al. 2012

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Leukocyte adhesion to endothelium plays a critical initiating role in inflammation. Berberine, an antiinflammatory natural compound, is known to attenuate lipopolysaccharide (LPS)-induced lung injury and improve survival of endotoxemic animals with mechanism not fully clarified. This study investigated the effects of berberine on the LPS-induced leukocyte-endothelial cell adhesion both in vivo and in vitro. We first established an animal model to observe the in vivo LPS-induced adhesion of leukocytes to the endothelium of venules in the lung tissue dose-dependently. Pretreatment of LPS-stimulated rats with berberine for 1 h reduced the leukocyte-endothelium adhesion and vascular cell adhesion molecule-l (VCAM-l) expression in lung. Pretreatment of LPS-stimulated vascular endothelial cells with berberine also dose-dependently decreased the number of adhered THP-l cells and VCAM-l expression at both RNA and protein levels. Berberine was further confirmed to inhibit the nuclear translocation and DNA binding activity of LPS-activated nuclear factor-kappa B (NF-kappa B). These data demonstrated an additional molecular mechanism for the profound anti-inflammatory effect of berberine.

show abstract

Cardiovascular and metabolic effects of Berberine

Cited by 81 publications

References 48 publications

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Metformin and metabolic diseases: a focus on hepatic aspects

Berberine Reduces Leukocyte Adhesion to Lps-Stimulated Endothelial Cells and Vcam-1 Expression Both In Vivo and In Vitro

Contact Info

Product

Resources

About